Hum Psychopharmacol. 2012 May;27(3):262-9. doi: 10.1002/hup.2216. Epub 2012 Feb 7.The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study.Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Ng C, Murray G, Stough C.SourceThe University of Melbourne, Department of Psychiatry, 2 Salisbury St., Richmond, Melbourne, Australia. [email protected]: Kava
(Piper methysticum) is a psychotropic plant medicine with history of
cultural and medicinal use. We conducted a study comparing the acute
neurocognitive, anxiolytic, and thymoleptic effects of a medicinal dose
of kava to a
benzodiazepine and explored for the first time specific genetic
polymorphisms, which may affect the psychotropic activity of
phytomedicines or benzodiazepines.METHODS: Twenty-two moderately anxious adults aged between 18 and 65 years were randomized to receive an acute dose of kava (180 mg of kavalactones), oxazepam (30 mg), and placebo 1 week apart in a crossover design trial.RESULTS: After exposure to cognitive tasks, a significant interaction was revealed between conditions on State-Trait Anxiety Inventory-State anxiety (p = 0.046, partial ŋ² = 0.14). In the oxazepam condition, there was a significant reduction in anxiety (p = 0.035), whereas there was no change in anxiety in the kava condition, and there was an increase in anxiety in the placebo condition. An increase in Bond-Lader "calmness" (p = 0.002) also occurred for the oxazepam condition. Kava
was found to have no negative effect on cognition, whereas a reduction
in alertness (p < 0.001) occurred in the oxazepam condition. Genetic
analyses provide tentative evidence that noradrenaline (SLC6A2)
transporter polymorphisms may have an effect on response to kava.CONCLUSION: Acute "medicinal level" doses of this particular kava
cultivar in naive users do not provide anxiolytic activity, although
the phytomedicine also appears to have no negative effects on cognition
This study is bad, bad bad. Did no one inform them of reverse tolerance?acute dosing probably won't work in the vast majority, this study highlights the biggest drawback of kava, Reverse tolerance. Anxiolysis from all the data takes about two weeks of steady dosing to achieve.
(Piper methysticum) is a psychotropic plant medicine with history of
cultural and medicinal use. We conducted a study comparing the acute
neurocognitive, anxiolytic, and thymoleptic effects of a medicinal dose
of kava to a
benzodiazepine and explored for the first time specific genetic
polymorphisms, which may affect the psychotropic activity of
phytomedicines or benzodiazepines.METHODS: Twenty-two moderately anxious adults aged between 18 and 65 years were randomized to receive an acute dose of kava (180 mg of kavalactones), oxazepam (30 mg), and placebo 1 week apart in a crossover design trial.RESULTS: After exposure to cognitive tasks, a significant interaction was revealed between conditions on State-Trait Anxiety Inventory-State anxiety (p = 0.046, partial ŋ² = 0.14). In the oxazepam condition, there was a significant reduction in anxiety (p = 0.035), whereas there was no change in anxiety in the kava condition, and there was an increase in anxiety in the placebo condition. An increase in Bond-Lader "calmness" (p = 0.002) also occurred for the oxazepam condition. Kava
was found to have no negative effect on cognition, whereas a reduction
in alertness (p < 0.001) occurred in the oxazepam condition. Genetic
analyses provide tentative evidence that noradrenaline (SLC6A2)
transporter polymorphisms may have an effect on response to kava.CONCLUSION: Acute "medicinal level" doses of this particular kava
cultivar in naive users do not provide anxiolytic activity, although
the phytomedicine also appears to have no negative effects on cognition
This study is bad, bad bad. Did no one inform them of reverse tolerance?acute dosing probably won't work in the vast majority, this study highlights the biggest drawback of kava, Reverse tolerance. Anxiolysis from all the data takes about two weeks of steady dosing to achieve.